Michael May

⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030. MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment. “This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.” Learn more about this research: bit.ly/4trr1xK @AACR

1/n Most productive 💡collaborative meeting with #likeminded colleagues friends - full 🟣 circle of older and new mentors #AACR26 @AACR @haochenz39 Benoit Rousseau @MarcHilmi David Tuveson Binbin Binbin Zheng Ying Long @MichaelMayMD @jakelee0711

No surprise! @EileenMOReilly handling it like pro she is! Thanks to my friend @christine_lovly for the photo. So much RAS excitement at #AACR26.

MSK gastrointestinal medical oncologist Dr. @EileenMOReilly speaks to a crowd about her late-breaking poster research on “Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic #pancreatic adenocarcinoma (mPDAC)” at #AACR26. @aacr

I've learned so much about the regulatory side of drug development through this fellowship, especially with daraxonrasib currently under evaluation for accelarated approval. Thank you to @AACR & @US_FDA for hosting me at #AACR26! Looking foward to meeting again soon at the FDA.

Fantastic work by Benoît Rousseau on unlocking dMMR phenotype in pMMR tumors using novel combinations to silence MMR proteins. ⁦@segaln⁩

🚨 An experimental, personalized vaccine using #mRNA to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group. New results from a phase 1 clinical trial, being presented at #AACR26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later. “These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines. Learn more about these findings: bit.ly/3QuIiaL @AACR

Very impressive tolerability and activity of Zoldonrasib in KRAS G12D mutant NSCLC. A lot of opportunities for combinability when almost all of the AEs are grade 1.

@CentralParkWMD quote in @TIME “ we are at an inflection point in pancreatic cancer” . Totally agree ! Perhaps this will be similar to the immune checkpoint moment for melanoma 15 years back that we are seeing in novel therapeutics for pancreas cancer !! 👏

Daraxonrasib with mOS of 13.2 months vs 6.7 for chemo (HR 0.4), the biggest ever leap forward in pancreatic cancer treatment! So excited to be starting a career in pancreatic cancer research, and to soon be able to offer this to my patients off trial! ir.revmed.com/news-releases/…

A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations. Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM. The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader. KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers. “This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily." Learn more about this research: bit.ly/4lSeoJa

🤯🤯 Huge congratulations to @CentralParkWMD for two first-author papers in NEJM and Nature Medicine - on the same day! Truly extraordinary contribution to the field. Proud to be part of this @MSKCancerCenter team! @EileenMOReilly @ciacobu

I learned so much writing this review of novel PDAC therapies with my brilliant mentors @EileenMOReilly & @CentralParkWMD. Amazing to have multiple targeted therapies with single agent activity. It's a great time to start a career in PDAC drug development. link.springer.com/article/10.100…

Grateful for everyone who supported team Fearless HBP's @Cycle4Survival fundraiser. Every donation, share, and message pushes pancreatic cancer research @MSKCancerCenter forward. Thank you for riding with me @CentralParkWMD @MarcHilmi @schoenfeld_j @jmsongmd @nasca_vincenzo

Calling on you as captain of Fearless #HBP #HumansBeyondPatients #sPARKLab Breakthroughs with #KRAS inhibitors and immune modulation are near in #PancreaticCancer but we need to learn more & go faster Ride with us & tell your story to fuel the mission 👉 mskcc.convio.net/goto/FearlessH…

On 8/10/25 my uncle Pete died from pancreatic cancer. Today I am working with @EileenMOReilly and @CentralParkWMD to improve treatments for this terrible disease. Please consider supporting MSKCC's research efforts through our Cycle for Survival team. secure2.convio.net/mskcc/site/TR?…

Our MSK HPB symposium is just one week away! Join us in NYC to learn and discuss the latest advances in mCRC and pancreas cancer. Register here: bit.ly/MSKHPB2025 @EileenMOReilly @MSKCME @BasGrootKoerkam @michael_lidsky @MichaelDAngeli2 @surgeonweiss @HopSTranCao

.@NatureGenet paper by @BizarMd @columbiacancer Cellular states associated with metastatic organotropism & survival in patients with #PancreaticCancer “pre-existing cellular states within primary tumors appear to guide organ-specific metastatic relapse” nature.com/articles/s4158…

nature.com/articles/s4158… We found that pancreatic cancer cell transcriptional profiles resemble their future metastatic niche, potentially enabling prediction of organotropism. The results of years of collaboration with @DrGManji @BizarMd @Morteza_C_H @Amich1122, and many others.

Tremendous thanks to our many collaborators @christinemphmd and @Jonathanwlee23 at @WCMLungCancer, @KCArbourMD Gregory Reily and Stephanie Bogdan at @MSKCancerCenter @DrDawnHershman @BHenickMD @CatherineShuMD and Ben May at @columbiacancer and and many others.

Patients and providers need inclusive clinical trials that tell us the efficacy and safety of novel agents across the full spectrum of patients likely to receive them. This is increasingly true in the era of targeted and ideally safer and better tolerated cancer therapies.

academic.oup.com/jnci/advance-a… We found that 60-70% of patients in a real world cohort of KRAS G12C mutant NSCLC would have been ineligible for trials of KRAS G12C inhibitors including most patients who received these therapeutics after their approval. @bherzbergmd @margaux_wooster